A systematic literature review of utility weights in wet age-related macular degeneration

Pearson, Isobel; Rycroft, Catherine; Irving, Adam; Ainsworth, Claire; Wittrup-Jensen, Kim

doi:10.3111/13696998.2013.839946

Cited by 14 publications

(9 citation statements)

References 21 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another disparity that might count is that the EQ-5D score presents societal values of health states whilst the TTO reflects patients’ evaluations. Our findings are in line with and confirm the conclusions of previous systematic reviews on utility measurement in wet AMD [ 19 , 20 ]. Pearson et al found that the TTO measurement is a better indicator of the impact of visual acuity on HRQOL than the EQ-5D.…”

Section: Discussionsupporting

confidence: 93%

“…Utilities are used to calculate the quality-adjusted life year (QALY) gains of different treatment strategies in cost-effectiveness analyses. Health state utility values in AMD were analysed in two recent systematic literature reviews and the time trade-off (TTO) method was found to be a suitable health state valuation technique in AMD [ 19 , 20 ]. The TTO consists of a hypothetical trade-off in which subjects are asked to indicate the number of life-years they would be willing to sacrify to avoid a well-defined poorer health state [ 21 – 23 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs

et al. 2017

View full text Add to dashboard Cite

BackgroundSubjective expectations regarding future health may influence patients’ judgement of current health and treatment effects, as well as adherence to therapies in chronic diseases. We aimed to explore subjective expectations on longevity and future health-related quality of life (HRQOL) of patients with age-related macular degeneration (AMD) treated with antiVEGF injections and analyse the influencing factors.MethodsConsecutive AMD patients in two ophthalmology centres were included. Demographics, clinical characteristics and informal care utilisation were recorded. Current health was evaluated by the EQ-5D generic health status questionnaire and time trade-off (TTO) methods. Happiness was measured on a visual analogue scale (VAS). Subjective life-expectancy and expected EQ-5D status at ages 70, 80 and 90 were surveyed. T-test was applied to compare subgroups and Pearson correlations were performed to analyse relationships between variables.ResultsOne hundred twenty two patients were involved (females 62%) with a mean (SD) age of 75.2 (7.9) years and disease duration of 2.9 (2.5) years. The majority were in AREDS-4 state, the better eye’s ETDRS was 64.7 (15.4). EQ-5D and TTO revealed moderate deterioration of health (0.66 vs. 0.72, p = 0.131), happiness VAS was 6.3 (2.2). Correlation between EQ-5D and ETDRS was moderate (R = 0.242, p < 0.05) and having both versus one eye in AREDS-4 resulted lower TTO (0.68 vs. 0.83; p = 0.013). Subjective life-expectancy did not differ significantly from statistical life-expectancy and had no significant impact on TTO. The self-estimated mean EQ-5D score was 0.60, 0.40 and 0.24 for ages 70, 80 and 90 which is lower than the population norm of age-groups 65–74, 75–84 and 85+ (0.77, 0.63 and 0.63, respectively). Age, gender, current EQ-5D, need for informal care and happiness were deterministic factors of subjective health expectations.ConclusionAMD patients with antiVEGF treatment have comparable HRQOL as the age-matched general public but expect a more severe deterioration of health with age. Older patients with worse HRQOL have worse subjective expectations. Exploring patients’ health expectations provides an opportunity for ophthalmologists to correct misperceptions and improve the quality of AMD care. Further studies should provide evidences on the relationship between subjective expectations and actual health outcomes, and on its impact on patients’ AMD-specific health behaviour.Electronic supplementary materialThe online version of this article (10.1186/s12877-017-0619-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Likewise, several studies have demonstrated a link between ocular surface disease related to glaucoma therapy and reduced QoL in glaucoma patients . Glaucoma and AMD each impact utility values; it is plausible that patients with both conditions have poorer preference‐based status than those with glaucoma alone.…”

Section: Discussionmentioning

confidence: 99%

“…Both glaucoma and AMD can cause significant limitations on patients' daily activities, profoundly affecting their quality of life (QoL). However, the additive impact of AMD on vision‐related activity limitation or preference‐based status in patients with glaucoma has not previously been quantified.…”

Section: Introductionmentioning

confidence: 99%

“…17 Visual loss from either condition can lead to social isolation from impaired driving, loss of independence and reduced social interaction. 8,18,19 Both glaucoma 14,16,[20][21][22][23] and AMD 10,18,[24][25][26][27] can cause significant limitations on patients' daily activities, profoundly affecting their quality of life (QoL). However, the additive impact of AMD on visionrelated activity limitation or preference-based status in patients with glaucoma has not previously been quantified.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of age‐related macular degeneration in patients with glaucoma: understanding the patients' perspective

Skalicky

Fenwick

Martin

et al. 2016

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis

Brown

Chaudhry

et al. 2021

JAMA Ophthalmol

View full text Add to dashboard Cite

IMPORTANCE Select research methods in cost-utility analysis (incremental cost-effectiveness analysis) might potentially bias against patient value (quality-adjusted life-year [QALY]) gain and cost-effectiveness associated with common ophthalmic interventions in disabled, elderly, and African American populations. OBJECTIVE To ascertain whether using nonpatient vision utilities and/or a maximum limit model constraining vision utility gain to the systemic comorbidity utility level biases against ophthalmic cost-utility outcomes. DESIGN, SETTING, AND PARTICIPANTSThis economic evaluation predominantly used data from the Center for Value-Based Medicine database to perform preference-based comparative effectiveness and cost-utility analyses for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease (ophthalmic patient utilities) and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain.

show abstract

A systematic literature review of utility weights in wet age-related macular degeneration

Cited by 14 publications

References 21 publications

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs

Impact of age‐related macular degeneration in patients with glaucoma: understanding the patients' perspective

Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis

Contact Info

Product

Resources

About